title: [The "Seville" Consensus Document on Alternatives to Allogenic Blood Transfusion. Sociedades españolas de Anestesiología (SEDAR), Medicina Intensiva (SEMICYUC), Hematología y Hemoterapia (AEHH), Transfusión sanguínea (SETS) Trombosis y Hemostasia (SETH)].
abstract: The Consensus Document on Alternatives to Allogenic Blood Transfusion (AABT) has been drawn up by a panel of experts from 5 scientific societies. The Spanish Societies of Anesthesiology (SEDAR), Critical Care Medicine and Coronary Units (SEMICYUC), Hematology and Hemotherapy (AEHH), Blood Transfusion (SETS) and Thrombosis and Hemostasis (SETH) have sponsored and participated in this Consensus Document. Alternatives to blood transfusion have been divided into pharmacological and non-pharmacological, with 4 modules and 12 topics. The main objective variable was the reduction of allogenic blood transfusions and/or the number of transfused patients. The extent to which this objective was achieved by each AABT was evaluated using the Delphi method, which classifies the grade of recommendation from A (supported by controlled studies) to E (non-controlled studies and expert opinion). The experts concluded that most of the indications for AABT were based on middle or low grades of recommendation, "C", "D", or "E", thus indicating the need for further controlled studies.
authors.forename: Ignacio
authors.initials: I
authors.lastname: Alberca
authors.forename: Ma Soledad
authors.initials: MS
authors.lastname: Asuero
authors.forename: José L
authors.initials: JL
authors.lastname: Bóveda
authors.forename: Nelly
authors.initials: N
authors.lastname: Carpio
authors.forename: Enric
authors.initials: E
authors.lastname: Contreras
authors.forename: Enrique
authors.initials: E
authors.lastname: Fernández-Mondéjar
authors.forename: Alejandro
authors.initials: A
authors.lastname: Forteza
authors.forename: José A
authors.initials: JA
authors.lastname: García-Erce
authors.forename: Abelardo
authors.initials: A
authors.lastname: García de Lorenzo
authors.forename: Carmen
authors.initials: C
authors.lastname: Gomar
authors.forename: Aurelio
authors.initials: A
authors.lastname: Gómez
authors.forename: Juan V
authors.initials: JV
authors.lastname: Llau
authors.forename: María F
authors.initials: MF
authors.lastname: López-Fernández
authors.forename: Victoria
authors.initials: V
authors.lastname: Moral
authors.forename: Manuel
authors.initials: M
authors.lastname: Muñoz
authors.forename: José A
authors.initials: JA
authors.lastname: Páramo
authors.forename: Pablo
authors.initials: P
authors.lastname: Torrabadella
authors.forename: Manuel
authors.initials: M
authors.lastname: Quintana
authors.forename: Calixto
authors.initials: C
authors.lastname: Sánchez
mesh_terms: D015119:Aminocaproic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007611:Aprotinin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016063:Blood Loss, Surgical / Q000517:prevention & control; D001802:Blood Substitutes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001804:Blood Transfusion, Autologous; D003102:Colloids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000077324:Crystalloid Solutions; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D015942:Factor VIIa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006438:Hemodilution; D006470:Hemorrhage / Q000188:drug therapy / Q000628:therapy*; D006490:Hemostatics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007501:Iron / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007552:Isotonic Solutions / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D057725:Operative Blood Salvage; D019106:Postoperative Hemorrhage / Q000188:drug therapy; D011292:Premedication; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014148:Tranexamic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000933:Antifibrinolytic Agents; D001802:Blood Substitutes; D003102:Colloids; D000077324:Crystalloid Solutions; D006397:Hematinics; D006490:Hemostatics; D007552:Isotonic Solutions; D011994:Recombinant Proteins; D014148:Tranexamic Acid; D007611:Aprotinin; C103587:recombinant FVIIa; D007501:Iron; D015942:Factor VIIa; D003894:Deamino Arginine Vasopressin; D015119:Aminocaproic Acid